Drug Database
MO

mometasone furoate (Monovo / H527722 / Mundoson)

✓ Approved

Almirall, S.A · NR3C1 · Small Molecule

What is mometasone furoate?

mometasone furoate is a small molecule developed by Almirall, S.A. It is approved for therapeutic indications via topical.

Drug Profile

Brand NamesMonovo, H527722, Mundoson
CompanyAlmirall, S.A
Drug ClassSmall Molecule
Molecular TargetNR3C1, NR3C2
RouteTopical
StatusApproved
Sources: ClinicalTrials.gov, Almirall, S.A

Mechanism of Action

Molecular Targets

mometasone furoate acts on 2 molecular targets:

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
NR3C2nuclear receptor subfamily 3 group C member 2 (NR3C2VIT, MR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

mometasone furoate is developed for 3 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Skin and subcutaneous tissue disordersDermatitis allergic✓ Approved
Skin and subcutaneous tissue disordersDermatitis atopic✓ Approved
Skin and subcutaneous tissue disordersPsoriasis✓ Approved

Related Research Articles

PubMedJournal of clinical medicine2026-07-15

Correction: Akiyama et al. Comparison of the Risk of Pneumonia Between Fluticasone Furoate/Umeclidinium/Vilanterol and Multiple-Inhaler Triple Therapy in Patients with COPD Using Health Insurance Claims Data: Final Analysis of Post-Marketing Database Surveillance in Japan. J. Clin. Med. 2025, 14, 4697.

Akiyama Shoko S, Oda Kenji K, Mizohata Hiroko H, Sasakura Natsuki N et al.

There was an error in the original publication [...].

PMID 42452781
Read full article →
PubMedJournal of family medicine and primary care2026-07-15

Awareness, knowledge, attitude, and behaviors related to topical corticosteroid use among population in Hail, Saudi Arabia: A cross-sectional study.

Aljaloud Luluh Zamil LZ, Altamimi Naif N, Alharthi Reem Marzouq S RMS, Alghamdi Mohammed Saeed Mohammed MSM et al.

Corticosteroids are widely used for inflammatory conditions, yet misuse and limited public awareness can cause preventable harm. In Hail, Saudi Arabia, community knowledge appears limited, warranting targeted assessment. To assess knowledge, awareness, attitudes, and use patterns of topical corticosteroids (TCSs) among adults in Hail, Saudi Arabia. We conducted a cross-sectional online survey (October 2024-March 2025) among adults aged ≥18 years. Of 535 respondents, 419 (78.0%) reported prior TCS use and were included in behavioral analyses, while 116 (21.0%) were non-users. Descriptive statistics summarized patterns, and bivariate analyses examined associations between awareness and behaviors. Prescription use was more common than self-medication (58.9% vs 41.1%), and most users applied corticosteroids once daily (60.6%). Mometasone was the most frequently reported agent (33.9%), although 36.8% could not name the product; acne, melasma, and tinea were common indications. Awareness was moderate: 62.8% recognized potency categories, and 55.4% were aware of adverse effects. Overall, 45.0% reported ≥1 adverse effect, most often mood changes, pruritus, increased thirst/urination, or skin thinning. Most had discontinued at least once (79.5%); tapering was more frequent than abrupt cessation (58.9% vs 41.1%), and relapse occurred in 23.7%, often within a week. Awareness aligned with safer practice: aware users were more likely to have a prescription (65.0% vs 48.7%) and to recognize adverse effects (73.8% vs 24.4%); prescribed users also tapered more often than they stopped abruptly (67.6% vs 43.9%). TCS use is prevalent in Hail and is accompanied by self-medication and important knowledge deficits. Strengthening pharmacist counseling, improving labeling, regulating access to higher-potency agents, and implementing community education initiatives may enhance safety and reduce avoidable adverse outcomes.

PMID 42453254
Read full article →
PubMedImmunity, inflammation and disease2026-07-14

Mometasone Furoate Alleviates PM2.5-Induced Pyroptosis of Nasal Mucosa Cells via Blocking JAK2/STAT3/AIM2 Inflammasome.

Shi Bin B, Liu Zhiqi Z, Le Ge G

Mometasone furoate (MF) is a widely used intranasal corticosteroid for the management of allergic and non-allergic rhinitis. Recent evidence suggests that its therapeutic efficacy may involve mechanisms beyond traditional anti-inflammatory actions, including modulation of death in nasal mucosa cells. This study aimed to investigate the therapeutic effects of MF on chronic rhinitis, elucidates the underlying molecular mechanisms, and explores its clinical implications in rhinitis management. Enzyme-linked immunosorbent assay was used to detect cytokine release. Reverse transcription quantitative PCR was applied for detecting mRNA expression. Immunofluorescence was used detect LC3 expression. Protein express was detected using Western blot. Lactate dehydrogenase leakage assay was used to detect cytotoxicity. Terminal deoxynucleotidyl transferase dUTP nick-end labeling assay was used to detect death of nasal mucosa cells (NMCs). Luciferase and chromatin immunoprecipitation assays were used to verify the interaction between signal transducer and activator of transcription 3 (STAT3) and absent in melanoma 2 (AIM2). MF significantly suppressed inflammatory response induced by PM2.5. MF suppressed PM2.5-induced cytotoxicity and pyroptosis of NMCs. Moreover, MF promotes the activation of autophagy. Mechanically, MF inhibited PM2.5-induced activation of Janus kinase 2/STAT3 signaling. STAT3 transcriptionally upregulated AIM2. The activation of AIM2 inflammasome attenuated the effects of MF and promoted the inflammation and pyroptosis of NMCs as well as suppressed the activation of autophagy. In summary, MF protects against chronic rhinitis via suppressing AIM2-dependent pyroptosis of NMCs. Therefore, MF can be a therapeutic strategy for chronic rhinitis.

PMID 42444306
Read full article →
PubMedExpert opinion on pharmacotherapy2026-07-14

Current perspectives on β2-adrenergic receptor agonists in asthma: navigating from track to track within GINA recommendations.

Calzetta Luigino L, Rogliani Paola P

Asthma treatment has long relied on short-acting β2-adrenergic receptor (β2-AR) agonists (SABA) such as salbutamol for as-needed relief, often without concurrent anti-inflammatory therapy. Emerging data link frequent SABA use to higher exacerbation rates and mortality. Current recommendations organize asthma treatment into Track 1, with as-needed inhaled corticosteroid (ICS)/formoterol used also as maintenance-and-reliever therapy, and Track 2, with SABA or ICS/SABA reliever plus separate maintenance; Track 1 is identified as the preferred option. This review evaluates β2-AR agonist use within the Track 1/Track 2 context. Randomized trials show as-needed ICS/formoterol reduces severe exacerbations more than SABA-based regimens, without a detectable mortality signal. Large observational evidence indicates that 3-5 SABA canisters per year already associates with increased mortality, with higher risk at 6-10 and ≥11 canisters per year. Contemporary trials and real-world studies reveal many patients on SABA-centered or fluticasone furoate/vilanterol regimens may reach these exposure levels, whereas ICS/formoterol regimens produce lower reliever use and fewer exacerbations. Where ICS/formoterol is accessible, Track 1 should be the default strategy. Clinicians should minimize SABA overuse, prioritize ICS/formoterol regimens, and advocate policies improving access to reduce preventable morbidity and mortality.

PMID 42444391
Read full article →
PubMedDalton transactions (Cambridge, England : 2003)2026-07-14

Fine-tuning of the properties of supported hydrogenation catalysts based on furoate Cu(II) complexes with aminopyridines as precursors.

Koshenskova Kseniya A KA, Novikov Dmitry V DV, Razvorotneva Lada S LS, Dolgushin Fedor M FM et al.

The creation of the "correct" surface in heterogeneous catalysis is an important condition for the optimal operation of a number of catalytic systems, for example, hydrogenation (nitrobenzene dicyclopentadiene). In this case, the interaction of the metal with the support plays a decisive role in the catalytic efficiency of the process. In the present work, a series of copper(II) complexes of the composition [Cu(fur)2(ampy)2]·L were synthesized, where fur- represents the anions 2Hfur (1 and 2) and 3Hfur (3 and 4); ampy = γ-aminopyridine (γ-ampy; 1 and 4) and α-aminopyridine (α-ampy; 2 and 3); and L = CH3CN (1). The crystalline products were isolated, and their structures were determined using the single-crystal X-ray diffraction method. According to X-ray data, it was established that the complexes with γ-ampy (1 and 4) are characterized by the formation of trans-isomers, whereas for α-ampy, the cis-configuration of the ligands is realized - the position of the amino groups in the α-ampy ligands is the main factor stabilizing the cis-structure of complexes 2 and 3. STA data of 1-4 revealed the volatility of trans-4, which has a smaller number of intermolecular hydrogen bonds, and quantum chemical calculations indicated high stability (-152.3 kcal mol-1). Crystallographic and geometric characteristics of trans-complexes 1 and 4 determined the formation of effective precatalytic surfaces (SEM data), allowing the hydrogenation of nitrobenzene (NB) and dicyclopentadiene (DCPD) to be carried out most efficiently under atmospheric pressure and low temperatures - the aniline yield was about 100%.

PMID 42444419
Read full article →
PubMedThe journal of allergy and clinical immunology. Global2026-07-13

Effect of once-daily ICS/LAMA/LABA triple therapy versus ICS/LABA on respiratory symptoms (E-RS: Asthma): Analysis of the phase IIIA CAPTAIN trial.

Pizzichini Emilio E, Brusselle Guy G, Crawford Jodie J, Inoue Hiromasa H et al.

Addition of the long-acting muscarinic antagonist umeclidinium (UMEC) to the inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) combination fluticasone furoate/vilanterol (FF/VI) improved lung function in adults with uncontrolled moderate to severe asthma in the CAPTAIN (Clinical study of Asthma Patients receiving Triple therapy through A single INhaler) study; however, the impact on symptoms requires further investigation. We sought to evaluate the effect of adding UMEC to FF/VI on asthma symptoms. The CAPTAIN study was a phase IIIA, randomized, controlled, 24- to 52-week study of patients with uncontrolled moderate to severe asthma despite ICS/LABA receiving once-daily single-inhaler FF/VI (100/25 or 200/25 μg) or FF/UMEC/VI (100/31.25/25, 100/62.5/25, 200/31.25/25, or 200/62.5/25 μg). Here, we compare the effect of pooled FF/UMEC 62.5/VI (100/62.5/25 and 200/62.5/25 μg) versus FF/VI (100/25 and 200/25 μg) on symptom control using prespecified analyses of change from baseline in Evaluating Respiratory Symptoms in Asthma (E-RS: Asthma) total and domain scores, and proportion of patients meeting an E-RS: Asthma total score responder threshold. We also performed post hoc analyses assessing the impact of baseline type 2 inflammation status on treatment response. Least-squares mean (95% CI) reductions from baseline in E-RS: Asthma total score exceeded the minimum clinically important difference (-2.0 units) and were numerically greater with FF/UMEC 62.5/VI (-2.89 [-3.15 to -2.64]; n = 814) versus FF/VI (-2.47 [-2.73 to -2.22]; n = 813). The proportion of responders (45% [n = 360] vs 41% [n = 327]) and odds of response (odds ratio, 1.18 [95% CI, 0.96 to 1.45]) were numerically greater with FF/UMEC 62.5/VI versus FF/VI. Similar trends were observed irrespective of type 2 status. Patients with symptomatic asthma may benefit from optimized treatment interventions, such as adding a long-acting muscarinic antagonist to ICS/LABA.

PMID 42438707
Read full article →

+2105 more articles available with a free account

Sign up free to view all articles →

Ask about mometasone furoate